WSB2

Summary

WSB2 (WD repeat and SOCS box containing 2, HGNC:19222) is a protein-coding gene on chromosome 12q24.23, encoding WD repeat and SOCS box-containing protein 2 (Q9NYS7). May be a substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.

This gene encodes a member of the WD-protein subfamily. The encoded protein contains five WD-repeats spanning most of the protein and an SOCS box in the C-terminus. The SOCS box may act as a bridge between specific substrate-binding domains and E3 ubiquitin protein ligases. Three transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 55884 — RefSeq curated summary.

At a glance

• Gene–disease (curated): complex neurodevelopmental disorder (Limited, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 20 total — 2 pathogenic
• MANE Select transcript: NM_018639

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19222
Approved symbol	WSB2
Name	WD repeat and SOCS box containing 2
Location	12q24.23
Locus type	gene with protein product
Status	Approved
Aliases	SBA2, MGC10210
Ensembl gene	ENSG00000176871
Ensembl biotype	protein_coding
Entrez	55884

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 9 protein_coding, 3 retained_intron, 2 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000315436, ENST00000441406, ENST00000535496, ENST00000536602, ENST00000536738, ENST00000537945, ENST00000540129, ENST00000542726, ENST00000543186, ENST00000543218, ENST00000544233, ENST00000614776, ENST00000900384, ENST00000927429, ENST00000927430, ENST00000962718

RefSeq mRNA: 3 — MANE Select: NM_018639 NM_001278557, NM_001278558, NM_018639

CCDS: CCDS61251, CCDS61252, CCDS9186

Canonical transcript exons

ENST00000315436 — 9 exons

Exon	Start	End
ENSE00001303814	118032687	118034358
ENSE00002241893	118061036	118061179
ENSE00003478142	118035214	118035324
ENSE00003484297	118043133	118043377
ENSE00003548200	118036338	118036510
ENSE00003589512	118052310	118052478
ENSE00003617943	118042841	118042972
ENSE00003627154	118034986	118035093
ENSE00003672656	118038288	118038388

Expression profiles

Bgee: expression breadth ubiquitous, 299 present calls, max score 98.99.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 47.0049 / max 382.0101, expressed in 1819 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
133533	40.4807	1816
133535	1.2721	855
133532	1.2592	826
133524	1.0477	600
133530	0.8865	546
133534	0.7452	447
133531	0.6540	422
133536	0.3205	118
133526	0.2552	101
133529	0.0305	11

Top tissues by expression

299 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
superior frontal gyrus	UBERON:0002661	98.99	gold quality
postcentral gyrus	UBERON:0002581	98.97	gold quality
orbitofrontal cortex	UBERON:0004167	98.93	gold quality
parietal lobe	UBERON:0001872	98.92	gold quality
entorhinal cortex	UBERON:0002728	98.92	gold quality
endothelial cell	CL:0000115	98.81	gold quality
Brodmann (1909) area 46	UBERON:0006483	98.78	gold quality
Brodmann (1909) area 23	UBERON:0013554	98.77	gold quality
cortical plate	UBERON:0005343	98.75	gold quality
medial globus pallidus	UBERON:0002477	98.66	gold quality
prefrontal cortex	UBERON:0000451	98.61	gold quality
substantia nigra pars compacta	UBERON:0001965	98.54	gold quality
lateral nuclear group of thalamus	UBERON:0002736	98.54	gold quality
globus pallidus	UBERON:0001875	98.51	gold quality
substantia nigra pars reticulata	UBERON:0001966	98.44	gold quality
frontal cortex	UBERON:0001870	98.37	gold quality
frontal lobe	UBERON:0016525	98.37	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	98.35	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	98.29	gold quality
cerebral cortex	UBERON:0000956	98.25	gold quality
neocortex	UBERON:0001950	98.23	gold quality
temporal lobe	UBERON:0001871	98.21	gold quality
Brodmann (1909) area 9	UBERON:0013540	98.16	gold quality
medulla oblongata	UBERON:0001896	98.10	gold quality
subthalamic nucleus	UBERON:0001906	98.01	gold quality
superior vestibular nucleus	UBERON:0007227	97.99	gold quality
telencephalon	UBERON:0001893	97.95	gold quality
Ammon’s horn	UBERON:0001954	97.94	gold quality
occipital lobe	UBERON:0002021	97.92	gold quality
lateral globus pallidus	UBERON:0002476	97.92	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-13	yes	144.52
E-MTAB-7249	no	3488.18
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

55 targeting WSB2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-221-3P	99.86	71.56	1329
HSA-MIR-222-3P	99.86	71.35	1337
HSA-MIR-3617-5P	99.75	69.41	1968
HSA-MIR-641	99.75	69.35	1975
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-187-5P	99.74	70.26	1404
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-6757-3P	99.63	66.88	1089
HSA-MIR-186-3P	99.51	66.24	1685
HSA-MIR-4696	99.48	67.48	1040
HSA-MIR-32-3P	99.36	68.20	2517
HSA-MIR-6507-5P	99.36	70.46	2524
HSA-MIR-185-5P	99.35	68.60	2497
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-6719-3P	99.29	67.78	1387
HSA-MIR-5589-3P	99.29	68.30	1443
HSA-MIR-6731-5P	99.28	67.42	2375
HSA-MIR-8085	99.28	67.56	2362
HSA-MIR-324-3P	99.26	66.31	1034
HSA-MIR-3125	99.14	68.49	2269
HSA-MIR-7151-3P	99.04	69.72	2370

Literature-anchored findings (GeneRIF, showing 6)

• SBA2 gene might be a promising novel biomarker of cell differentiation in colorectal cancer and its biological features need further studies. (PMID:11819827)
• This report provides the first evidence that WSB-2 is a regulator of IL-21R expression and IL-21-induced signal transduction. (PMID:20059963)
• This is the first report to demonstrate the effects of WSB2 on melanoma cell function. (PMID:31103822)
• miR285p inhibits the migration of breast cancer by regulating WSB2. (PMID:32945370)
• Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma. (PMID:38177295)
• WSB1/2 target chromatin-bound lysine-methylated RelA for proteasomal degradation and NF-kappaB termination. (PMID:38452206)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	wsb2	ENSDARG00000058608
mus_musculus	Wsb2	ENSMUSG00000029364
rattus_norvegicus	Wsb2	ENSRNOG00000001135

Paralogs (1): WSB1 (ENSG00000109046)

Protein

Protein identifiers

WD repeat and SOCS box-containing protein 2 — Q9NYS7 (reviewed: Q9NYS7)

Alternative names: CS box-containing WD protein

All UniProt accessions (5): Q9NYS7, F5GXB6, F5H024, F5H280, F5H2L7

UniProt curated annotations — full annotation on UniProt →

Function. May be a substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.

Domain organisation. The SOCS box domain mediates the interaction with the Elongin BC complex, an adapter module in different E3 ubiquitin ligase complexes.

Pathway. Protein modification; protein ubiquitination.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9NYS7-1	1	yes
Q9NYS7-2	2
Q9NYS7-3	3

RefSeq proteins (3): NP_001265486, NP_001265487, NP_061109* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001496	SOCS_box	Domain
IPR001680	WD40_rpt	Repeat
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR019775	WD40_repeat_CS	Conserved_site
IPR020472	WD40_PAC1	Repeat
IPR036036	SOCS_box-like_dom_sf	Homologous_superfamily
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily
IPR051983	WSB_SOCS-box_domain	Family

Pfam: PF00400, PF07525

UniProt features (14 total): repeat 7, splice variant 2, sequence conflict 2, chain 1, domain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NYS7-F1	84.84	0.68

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-8951664	Neddylation

MSigDB gene sets: 236 (showing top): GCM_MAP4K4, BORCZUK_MALIGNANT_MESOTHELIOMA_UP, BERENJENO_ROCK_SIGNALING_NOT_VIA_RHOA_DN, YAATNRNNNYNATT_UNKNOWN, GCM_GSPT1, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, HASLINGER_B_CLL_WITH_MUTATED_VH_GENES, MITSIADES_RESPONSE_TO_APLIDIN_DN, DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, TGACATY_UNKNOWN, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_PROTEIN_POLYUBIQUITINATION, TATA_C, GCM_NF2

GO Biological Process (3): protein polyubiquitination (GO:0000209), intracellular signal transduction (GO:0035556), protein ubiquitination (GO:0016567)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein ubiquitination	1
intracellular anatomical structure	1
signal transduction	1
protein modification by small protein conjugation	1
binding	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1723 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
WSB2	MARCHF5	Q9NX47	616
WSB2	DRAP1	Q14919	519
WSB2	ASB3	Q9Y575	470
WSB2	FAM168B	A1KXE4	463
WSB2	RNF7	Q9UBF6	419
WSB2	SLC67A1-AS	Q8N1D0	417
WSB2	DCAF5	Q96JK2	396
WSB2	DCAF16	Q9NXF7	387
WSB2	ASB12	Q8WXK4	385
WSB2	CMTM4	Q8IZR5	384
WSB2	PCMTD2	Q9NV79	383
WSB2	LRRC41	Q15345	381
WSB2	RAB40A	Q8WXH6	375
WSB2	SOCS7	O14512	369
WSB2	CUL5	Q93034	362

IntAct

33 interactions, top by confidence:

A	B	Type	Score
WSB2	SNIP1	psi-mi:“MI:0914”(association)	0.640
WSB2	PFDN2	psi-mi:“MI:0915”(physical association)	0.560
WSB2	PFDN5	psi-mi:“MI:0915”(physical association)	0.560
WSB2	UBB	psi-mi:“MI:0914”(association)	0.530
RNF7	SOCS7	psi-mi:“MI:0914”(association)	0.530
WSB2	BCL2L1	psi-mi:“MI:0914”(association)	0.530
HSP90AB1	WSB2	psi-mi:“MI:0915”(physical association)	0.400
WSB2	FKBP5	psi-mi:“MI:0915”(physical association)	0.400
WSB2	Hacd3	psi-mi:“MI:0915”(physical association)	0.400
WSB2	HSF2	psi-mi:“MI:0915”(physical association)	0.400
NUDC	WSB2	psi-mi:“MI:0915”(physical association)	0.400
WSB2	NUDCD3	psi-mi:“MI:0915”(physical association)	0.400
	WSB2	psi-mi:“MI:0915”(physical association)	0.400
WSB2	SGTA	psi-mi:“MI:0915”(physical association)	0.400
WSB2	Usp19	psi-mi:“MI:0915”(physical association)	0.400
STIP1	WSB2	psi-mi:“MI:0915”(physical association)	0.400
FKBPL	WSB2	psi-mi:“MI:0915”(physical association)	0.400
CACYBP	WSB2	psi-mi:“MI:0915”(physical association)	0.400
WSB2	NUDCD2	psi-mi:“MI:0915”(physical association)	0.400
WSB2	AARSD1	psi-mi:“MI:0915”(physical association)	0.400
WSB2	PPP5C	psi-mi:“MI:0915”(physical association)	0.400
CUL5	DDX3X	psi-mi:“MI:0914”(association)	0.350
WSB2	ARIH2	psi-mi:“MI:0914”(association)	0.350
RNF7	SOCS2	psi-mi:“MI:0914”(association)	0.350
BCL2L1	UBB	psi-mi:“MI:0914”(association)	0.350
WSB2	ELOB	psi-mi:“MI:0914”(association)	0.350

BioGRID (593): SNIP1 (Affinity Capture-MS), CLASRP (Affinity Capture-MS), ACIN1 (Affinity Capture-MS), CCDC9 (Affinity Capture-MS), CUL5 (Affinity Capture-MS), ZC3H14 (Affinity Capture-MS), ARIH2 (Affinity Capture-MS), C17orf85 (Affinity Capture-MS), UBB (Affinity Capture-MS), PNN (Affinity Capture-MS), ISY1 (Affinity Capture-MS), RNPS1 (Affinity Capture-MS), NKTR (Affinity Capture-MS), AMBRA1 (Affinity Capture-MS), SUPT6H (Affinity Capture-MS)

ESM2 similar proteins: A4FUF0, A4Q9F4, B0K012, E9PTA2, O15315, O35719, O43502, O54804, O54929, O94759, P0C0T1, P42694, Q0V8J1, Q0VGM9, Q3U2J5, Q3ZBL5, Q49A26, Q5BIM1, Q5R7T2, Q5RJZ1, Q5RKH0, Q5ZIA0, Q5ZLS7, Q6DC64, Q6DFV5, Q6IE70, Q6NYU2, Q6P4H8, Q7Z624, Q80VL1, Q86W50, Q8BYN3, Q8CIW5, Q8NHH1, Q8R1C6, Q8R1G1, Q8R2J9, Q8R2Y8, Q91YD4, Q922P9

Diamond homologs: A0CH87, A0DB19, A1CF18, A1CUD6, A7S338, A8NEG8, A8XZJ9, A9V790, B0LSW3, B0XM00, B2AEZ5, B2B766, B2VWG7, B3MEY6, B3NPW0, B3S4I5, B4GAJ1, B4HSL3, B4JWA1, B4KT48, B4LQ21, B4MY65, B4P6P9, B4QHG6, B5X3C4, B5X3Z6, B6GZD3, B6HP56, B6QC06, B7FNU7, B7PS00, B8N9H4, B8P4B0, B8PD53, B9WD30, C0NRC6, C0S902, C1GB49, C3XVT5, C4Q0P6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 28 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Neddylation	6	13.5×	4e-04
Antigen processing: Ubiquitination & Proteasome degradation	6	10.6×	9e-04

GO biological processes:

GO term	Partners	Fold	FDR
protein folding	7	27.8×	1e-06
proteasome-mediated ubiquitin-dependent protein catabolic process	6	12.0×	6e-04
protein ubiquitination	7	11.2×	3e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

20 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	11
Likely benign	1
Benign	2

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
4819262	NM_018639.5(WSB2):c.1121G>A (p.Arg374Gln)	Pathogenic
4819263	WSB2, 2-BP DEL, 1187AA	Pathogenic

SpliceAI

1137 predictions. Top by Δscore:

Variant	Effect	Δscore
12:118034984:AC:A	donor_gain	1.0000
12:118034985:CC:C	donor_gain	1.0000
12:118035320:TGTGG:T	acceptor_gain	1.0000
12:118035322:TGG:T	acceptor_gain	1.0000
12:118035323:GG:G	acceptor_gain	1.0000
12:118035325:C:CC	acceptor_gain	1.0000
12:118036331:T:TA	donor_gain	1.0000
12:118036336:A:AC	donor_gain	1.0000
12:118036337:C:CT	donor_gain	1.0000
12:118036508:GACC:G	acceptor_loss	1.0000
12:118036510:CCTG:C	acceptor_loss	1.0000
12:118038280:AGACT:A	donor_loss	1.0000
12:118038281:GACTC:G	donor_loss	1.0000
12:118038282:ACTC:A	donor_loss	1.0000
12:118038283:CTCAC:C	donor_loss	1.0000
12:118038286:A:AC	donor_gain	1.0000
12:118038286:ACC:A	donor_loss	1.0000
12:118038287:C:CC	donor_gain	1.0000
12:118038287:CCGA:C	donor_gain	1.0000
12:118038387:ACC:A	acceptor_loss	1.0000
12:118038390:T:C	acceptor_loss	1.0000
12:118038394:A:T	acceptor_gain	1.0000
12:118042834:C:A	donor_gain	1.0000
12:118052308:A:AC	donor_gain	1.0000
12:118052309:C:CC	donor_gain	1.0000
12:118052309:CAA:C	donor_gain	1.0000
12:118052479:C:CC	acceptor_gain	1.0000
12:118061031:CTCA:C	donor_loss	1.0000
12:118061032:TCACC:T	donor_loss	1.0000
12:118061033:CA:C	donor_loss	1.0000

AlphaMissense

2644 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:118034987:C:A	G351W	1.000
12:118034992:G:T	A349D	1.000
12:118036375:A:G	W266R	1.000
12:118036375:A:T	W266R	1.000
12:118042876:T:A	D175V	1.000
12:118042877:C:G	D175H	1.000
12:118042888:G:A	S171F	1.000
12:118042888:G:T	S171Y	1.000
12:118052367:G:T	A42D	1.000
12:118034335:A:G	F359S	0.999
12:118034986:C:T	G351E	0.999
12:118035080:A:G	W320R	0.999
12:118035080:A:T	W320R	0.999
12:118036373:C:A	W266C	0.999
12:118036373:C:G	W266C	0.999
12:118036404:G:C	T256R	0.999
12:118036404:G:T	T256K	0.999
12:118036410:A:G	L254P	0.999
12:118036410:A:T	L254H	0.999
12:118036501:A:G	W224R	0.999
12:118036501:A:T	W224R	0.999
12:118038353:A:G	W199R	0.999
12:118038353:A:T	W199R	0.999
12:118042859:A:G	W181R	0.999
12:118042859:A:T	W181R	0.999
12:118042864:C:G	R179P	0.999
12:118042867:A:G	L178P	0.999
12:118042876:T:G	D175A	0.999
12:118042883:A:G	S173P	0.999
12:118042889:A:G	S171P	0.999

dbSNP variants (sampled 300 via entrez): RS1000020880 (12:118062828 T>G), RS1000209611 (12:118042103 T>C), RS1000366007 (12:118060928 G>A), RS1000441297 (12:118048219 G>A,T), RS1000793519 (12:118057640 G>T), RS1000828457 (12:118040722 G>A), RS1000854068 (12:118035570 G>A,T), RS1000862260 (12:118058757 C>A,T), RS1000881442 (12:118052844 A>G), RS1000980272 (12:118059540 C>G), RS1001032612 (12:118034017 A>G), RS1001063098 (12:118033768 A>C), RS1001182249 (12:118047237 A>G), RS1001276497 (12:118047208 G>C,T), RS1001291494 (12:118041163 A>G)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
complex neurodevelopmental disorder	Limited	Autosomal recessive

Mondo (1): complex neurodevelopmental disorder (MONDO:0100038)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST012015_5	Chronic rhinosinusitis	2.000000e-06
GCST90002403_460	Red blood cell count	4.000000e-10

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004305	erythrocyte count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, increases methylation	3
lead acetate	affects cotreatment, decreases expression, increases expression	2
sodium arsenite	decreases expression, increases abundance, increases expression	2
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	2
Acrolein	increases abundance, affects cotreatment, increases oxidation	2
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, decreases expression	2
Ozone	affects cotreatment, increases oxidation, increases abundance	2
GSK-J4	increases expression	1
bisphenol F	increases expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
uranyl acetate	affects expression	1
bisphenol A	increases expression	1
methylselenic acid	decreases expression	1
zinc protoporphyrin	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
bisphenol S	affects cotreatment, increases expression	1
Temozolomide	decreases expression	1
Arsenic Trioxide	decreases expression	1
Acetaminophen	decreases expression	1
Arsenic	decreases expression, increases abundance	1
Coumestrol	decreases expression	1
Dexamethasone	increases expression, affects cotreatment	1
Diazinon	decreases methylation	1
Diethylstilbestrol	increases expression	1
Hydrogen Peroxide	affects expression	1
Indomethacin	affects cotreatment, increases expression	1
Lead	affects expression	1
Tobacco Smoke Pollution	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2LI	Abcam HeLa WSB2 KO	Cancer cell line	Female

Clinical trials (associated diseases)

2 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT06310681	Not specified	COMPLETED	Pilot Testing of a Co-adapted Group Programme for Parents/Carers of Children With Complex Neurodisability
NCT07303049	Not specified	NOT_YET_RECRUITING	Cognitive Benefit of Intensive Rehabilitation Using Rhythmic Music Training in Children With Complex Neurodevelopmental Disorder